0.1815 USD
-0.1 (-34.95%)
0.1731 USD
-0.01 (-4.63%)
Overall AFMD gets a fundamental rating of 2 out of 10. We evaluated AFMD against 525 industry peers in the Biotechnology industry. AFMD may be in some trouble as it scores bad on both profitability and health. AFMD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
- AFMD had negative earnings in the past year.
- In the past year AFMD has reported a negative cash flow from operations.
- In the past 5 years AFMD always reported negative net income.
- In the past 5 years AFMD always reported negative operating cash flow.
1.2 Ratios
- AFMD has a worse Return On Assets (-175.10%) than 87.32% of its industry peers.
- Looking at the Return On Equity, with a value of -406.92%, AFMD is doing worse than 75.89% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -175.1% | ||
| ROE | -406.92% | ||
| ROIC | N/A |
ROA(3y)-59.16%
ROA(5y)-45.97%
ROE(3y)-93.94%
ROE(5y)-84.6%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- With an excellent Gross Margin value of 789.74%, AFMD belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
- In the last couple of years the Gross Margin of AFMD has declined.
- AFMD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 789.74% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.76%
GM growth 5Y-2.54%
2. Health
2.1 Basic Checks
- AFMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
- AFMD has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 1 year ago, AFMD has a worse debt to assets ratio.
2.2 Solvency
- Based on the Altman-Z score of -4.35, we must say that AFMD is in the distress zone and has some risk of bankruptcy.
- AFMD has a Altman-Z score (-4.35) which is comparable to the rest of the industry.
- A Debt/Equity ratio of 0.35 indicates that AFMD is not too dependend on debt financing.
- The Debt to Equity ratio of AFMD (0.35) is worse than 73.04% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.35 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -4.35 |
ROIC/WACCN/A
WACC6.81%
2.3 Liquidity
- A Current Ratio of 1.93 indicates that AFMD should not have too much problems paying its short term obligations.
- With a Current ratio value of 1.93, AFMD is not doing good in the industry: 76.79% of the companies in the same industry are doing better.
- AFMD has a Quick Ratio of 1.93. This is a normal value and indicates that AFMD is financially healthy and should not expect problems in meeting its short term obligations.
- AFMD has a Quick ratio of 1.93. This is in the lower half of the industry: AFMD underperforms 75.36% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.93 | ||
| Quick Ratio | 1.93 |
3. Growth
3.1 Past
- AFMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 42.15%, which is quite impressive.
- The Revenue for AFMD has decreased by -95.39% in the past year. This is quite bad
- Measured over the past years, AFMD shows a very negative growth in Revenue. The Revenue has been decreasing by -19.00% on average per year.
EPS 1Y (TTM)42.15%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.25%
Revenue 1Y (TTM)-95.39%
Revenue growth 3Y-33.67%
Revenue growth 5Y-19%
Sales Q2Q%-92.1%
3.2 Future
- The Earnings Per Share is expected to grow by 11.18% on average over the next years. This is quite good.
- Based on estimates for the next years, AFMD will show a very strong growth in Revenue. The Revenue will grow by 35.57% on average per year.
EPS Next Y40.97%
EPS Next 2Y28.77%
EPS Next 3Y19.02%
EPS Next 5Y11.18%
Revenue Next Year-81.84%
Revenue Next 2Y-23.09%
Revenue Next 3Y14.98%
Revenue Next 5Y35.57%
3.3 Evolution
- The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- The Price/Earnings Ratio is negative for AFMD. In the last year negative earnings were reported.
- Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AFMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A more expensive valuation may be justified as AFMD's earnings are expected to grow with 19.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.77%
EPS Next 3Y19.02%
5. Dividend
5.1 Amount
- AFMD does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
AFFIMED NV / AFMD FAQ
What is the fundamental rating for AFMD stock?
ChartMill assigns a fundamental rating of 2 / 10 to AFMD.
What is the valuation status of AFFIMED NV (AFMD) stock?
ChartMill assigns a valuation rating of 0 / 10 to AFFIMED NV (AFMD). This can be considered as Overvalued.
What is the profitability of AFMD stock?
AFFIMED NV (AFMD) has a profitability rating of 1 / 10.
What is the earnings growth outlook for AFFIMED NV?
The Earnings per Share (EPS) of AFFIMED NV (AFMD) is expected to grow by 40.97% in the next year.